NCT00855413View on ClinicalTrials.gov

HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine

PHASE4TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Acute HIV InfectionHIV Infections
Interventions
DRUG

Darunavir

800 mg orally once daily

DRUG

Ritonavir

100 mg orally once daily

DRUG

Etravirine

200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen

Trial Locations (2)

27599

The University of North Carolina - Chapel Hill, Chapel Hill

27707

Duke University, Durham

Sponsors

Collaborators (1)

Janssen Pharmaceuticals
All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER